organization · Reporting owner
Biodyne Holding, S.A.
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
enVVeno Medical Corp
Report date June 11, 2020 · Filed October 02, 2020
Section 16 reporting ended · disclosed 2020-10-02. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,405,433 |
Ending reported balance
After 2020-08-21 transaction · row 27
27 source rows · reconciled sequenceRow 1 · 2020-06-11 · Sale · Disposed 100,000 · Balance 3,255,433 F1: 1,950,000 is the total number of shares sold and these shares were sold in multiple transactions at an average price of $0.38. The reporting person undertakes to provide to Hancock Laboratories Jaffe, Inc., any security holder of Hancock Jaffe Laboratories, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate transaction at the price set forth in footnote (1) to this Form 4. Row 2 · 2020-06-15 · Sale · Disposed 100,000 · Balance 3,155,433 F1: 1,950,000 is the total number of shares sold and these shares were sold in multiple transactions at an average price of $0.38. The reporting person undertakes to provide to Hancock Laboratories Jaffe, Inc., any security holder of Hancock Jaffe Laboratories, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate transaction at the price set forth in footnote (1) to this Form 4. Row 3 · 2020-06-16 · Sale · Disposed 150,000 · Balance 3,005,433 F1: 1,950,000 is the total number of shares sold and these shares were sold in multiple transactions at an average price of $0.38. The reporting person undertakes to provide to Hancock Laboratories Jaffe, Inc., any security holder of Hancock Jaffe Laboratories, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate transaction at the price set forth in footnote (1) to this Form 4. Row 4 · 2020-06-17 · Sale · Disposed 203,100 · Balance 2,802,333 F1: 1,950,000 is the total number of shares sold and these shares were sold in multiple transactions at an average price of $0.38. The reporting person undertakes to provide to Hancock Laboratories Jaffe, Inc., any security holder of Hancock Jaffe Laboratories, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate transaction at the price set forth in footnote (1) to this Form 4. Row 5 · 2020-06-18 · Sale · Disposed 61,640 · Balance 2,740,693 F1: 1,950,000 is the total number of shares sold and these shares were sold in multiple transactions at an average price of $0.38. The reporting person undertakes to provide to Hancock Laboratories Jaffe, Inc., any security holder of Hancock Jaffe Laboratories, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate transaction at the price set forth in footnote (1) to this Form 4. Row 6 · 2020-06-19 · Sale · Disposed 80,000 · Balance 2,660,693 F1: 1,950,000 is the total number of shares sold and these shares were sold in multiple transactions at an average price of $0.38. The reporting person undertakes to provide to Hancock Laboratories Jaffe, Inc., any security holder of Hancock Jaffe Laboratories, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate transaction at the price set forth in footnote (1) to this Form 4. Row 7 · 2020-06-22 · Sale · Disposed 63,186 · Balance 2,597,507 F1: 1,950,000 is the total number of shares sold and these shares were sold in multiple transactions at an average price of $0.38. The reporting person undertakes to provide to Hancock Laboratories Jaffe, Inc., any security holder of Hancock Jaffe Laboratories, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate transaction at the price set forth in footnote (1) to this Form 4. Row 8 · 2020-06-23 · Sale · Disposed 80,000 · Balance 2,517,507 F1: 1,950,000 is the total number of shares sold and these shares were sold in multiple transactions at an average price of $0.38. The reporting person undertakes to provide to Hancock Laboratories Jaffe, Inc., any security holder of Hancock Jaffe Laboratories, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate transaction at the price set forth in footnote (1) to this Form 4. Row 9 · 2020-06-24 · Sale · Disposed 55,530 · Balance 2,461,977 F1: 1,950,000 is the total number of shares sold and these shares were sold in multiple transactions at an average price of $0.38. The reporting person undertakes to provide to Hancock Laboratories Jaffe, Inc., any security holder of Hancock Jaffe Laboratories, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate transaction at the price set forth in footnote (1) to this Form 4. Row 10 · 2020-06-25 · Sale · Disposed 100,000 · Balance 2,361,977 F1: 1,950,000 is the total number of shares sold and these shares were sold in multiple transactions at an average price of $0.38. The reporting person undertakes to provide to Hancock Laboratories Jaffe, Inc., any security holder of Hancock Jaffe Laboratories, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate transaction at the price set forth in footnote (1) to this Form 4. Row 11 · 2020-06-26 · Sale · Disposed 80,000 · Balance 2,281,977 F1: 1,950,000 is the total number of shares sold and these shares were sold in multiple transactions at an average price of $0.38. The reporting person undertakes to provide to Hancock Laboratories Jaffe, Inc., any security holder of Hancock Jaffe Laboratories, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate transaction at the price set forth in footnote (1) to this Form 4. Row 12 · 2020-06-29 · Sale · Disposed 68,094 · Balance 2,213,883 F1: 1,950,000 is the total number of shares sold and these shares were sold in multiple transactions at an average price of $0.38. The reporting person undertakes to provide to Hancock Laboratories Jaffe, Inc., any security holder of Hancock Jaffe Laboratories, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate transaction at the price set forth in footnote (1) to this Form 4. Row 13 · 2020-07-01 · Sale · Disposed 45,000 · Balance 2,168,883 F1: 1,950,000 is the total number of shares sold and these shares were sold in multiple transactions at an average price of $0.38. The reporting person undertakes to provide to Hancock Laboratories Jaffe, Inc., any security holder of Hancock Jaffe Laboratories, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate transaction at the price set forth in footnote (1) to this Form 4. Row 14 · 2020-07-02 · Sale · Disposed 57,000 · Balance 2,111,883 F1: 1,950,000 is the total number of shares sold and these shares were sold in multiple transactions at an average price of $0.38. The reporting person undertakes to provide to Hancock Laboratories Jaffe, Inc., any security holder of Hancock Jaffe Laboratories, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate transaction at the price set forth in footnote (1) to this Form 4. Row 15 · 2020-07-06 · Sale · Disposed 6,450 · Balance 2,105,433 F1: 1,950,000 is the total number of shares sold and these shares were sold in multiple transactions at an average price of $0.38. The reporting person undertakes to provide to Hancock Laboratories Jaffe, Inc., any security holder of Hancock Jaffe Laboratories, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate transaction at the price set forth in footnote (1) to this Form 4. Row 16 · 2020-07-16 · Sale · Disposed 50,000 · Balance 2,055,433 F1: 1,950,000 is the total number of shares sold and these shares were sold in multiple transactions at an average price of $0.38. The reporting person undertakes to provide to Hancock Laboratories Jaffe, Inc., any security holder of Hancock Jaffe Laboratories, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate transaction at the price set forth in footnote (1) to this Form 4. Row 17 · 2020-07-17 · Sale · Disposed 50,000 · Balance 2,005,433 F1: 1,950,000 is the total number of shares sold and these shares were sold in multiple transactions at an average price of $0.38. The reporting person undertakes to provide to Hancock Laboratories Jaffe, Inc., any security holder of Hancock Jaffe Laboratories, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate transaction at the price set forth in footnote (1) to this Form 4. Row 18 · 2020-07-20 · Sale · Disposed 150,000 · Balance 1,855,433 F1: 1,950,000 is the total number of shares sold and these shares were sold in multiple transactions at an average price of $0.38. The reporting person undertakes to provide to Hancock Laboratories Jaffe, Inc., any security holder of Hancock Jaffe Laboratories, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate transaction at the price set forth in footnote (1) to this Form 4. Row 19 · 2020-07-21 · Sale · Disposed 50,000 · Balance 1,805,433 F1: 1,950,000 is the total number of shares sold and these shares were sold in multiple transactions at an average price of $0.38. The reporting person undertakes to provide to Hancock Laboratories Jaffe, Inc., any security holder of Hancock Jaffe Laboratories, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate transaction at the price set forth in footnote (1) to this Form 4. Row 20 · 2020-07-30 · Sale · Disposed 25,000 · Balance 1,780,433 F1: 1,950,000 is the total number of shares sold and these shares were sold in multiple transactions at an average price of $0.38. The reporting person undertakes to provide to Hancock Laboratories Jaffe, Inc., any security holder of Hancock Jaffe Laboratories, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate transaction at the price set forth in footnote (1) to this Form 4. Row 21 · 2020-07-31 · Sale · Disposed 5,000 · Balance 1,775,433 F1: 1,950,000 is the total number of shares sold and these shares were sold in multiple transactions at an average price of $0.38. The reporting person undertakes to provide to Hancock Laboratories Jaffe, Inc., any security holder of Hancock Jaffe Laboratories, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate transaction at the price set forth in footnote (1) to this Form 4. Row 22 · 2020-08-03 · Sale · Disposed 70,000 · Balance 1,705,433 F1: 1,950,000 is the total number of shares sold and these shares were sold in multiple transactions at an average price of $0.38. The reporting person undertakes to provide to Hancock Laboratories Jaffe, Inc., any security holder of Hancock Jaffe Laboratories, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate transaction at the price set forth in footnote (1) to this Form 4. Row 23 · 2020-08-14 · Sale · Disposed 50,000 · Balance 1,655,433 F1: 1,950,000 is the total number of shares sold and these shares were sold in multiple transactions at an average price of $0.38. The reporting person undertakes to provide to Hancock Laboratories Jaffe, Inc., any security holder of Hancock Jaffe Laboratories, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate transaction at the price set forth in footnote (1) to this Form 4. Row 24 · 2020-08-18 · Sale · Disposed 50,000 · Balance 1,605,433 F1: 1,950,000 is the total number of shares sold and these shares were sold in multiple transactions at an average price of $0.38. The reporting person undertakes to provide to Hancock Laboratories Jaffe, Inc., any security holder of Hancock Jaffe Laboratories, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate transaction at the price set forth in footnote (1) to this Form 4. Row 25 · 2020-08-19 · Sale · Disposed 50,000 · Balance 1,555,433 F1: 1,950,000 is the total number of shares sold and these shares were sold in multiple transactions at an average price of $0.38. The reporting person undertakes to provide to Hancock Laboratories Jaffe, Inc., any security holder of Hancock Jaffe Laboratories, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate transaction at the price set forth in footnote (1) to this Form 4. Row 26 · 2020-08-20 · Sale · Disposed 75,000 · Balance 1,480,433 F1: 1,950,000 is the total number of shares sold and these shares were sold in multiple transactions at an average price of $0.38. The reporting person undertakes to provide to Hancock Laboratories Jaffe, Inc., any security holder of Hancock Jaffe Laboratories, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate transaction at the price set forth in footnote (1) to this Form 4. Row 27 · 2020-08-21 · Sale · Disposed 75,000 · Balance 1,405,433 F1: 1,950,000 is the total number of shares sold and these shares were sold in multiple transactions at an average price of $0.38. The reporting person undertakes to provide to Hancock Laboratories Jaffe, Inc., any security holder of Hancock Jaffe Laboratories, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate transaction at the price set forth in footnote (1) to this Form 4. |
Filing footnotes · ownership attribution and instrument terms
F1: 1,950,000 is the total number of shares sold and these shares were sold in multiple transactions at an average price of $0.38. The reporting person undertakes to provide to Hancock Laboratories Jaffe, Inc., any security holder of Hancock Jaffe Laboratories, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate transaction at the price set forth in footnote (1) to this Form 4.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 21, 2020 Filed Oct 2, 2020 01:25 UTC | enVVeno Medical Corp HJLI · Entity 8104 | SaleCommon Stock | 75,000 | $0.38 | $28,500.00 |
DisclosureSEC source: 0001493152-20-018750 · ownership.xml · nonDerivative · entry 27 Biodyne Holding, S.A. · CIK 0001730174 · Former 10% Owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,405,433 F1 · price: 1,950,000 is the total number of shares sold and these shares were sold in multiple transactions at an average price of $0.38. The reporting person undertakes to provide to Hancock Laboratories Jaffe, Inc., any security holder of Hancock Jaffe Laboratories, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate transaction at the price set forth in footnote (1) to this Form 4. Read SEC document |
| August 20, 2020 Filed Oct 2, 2020 01:25 UTC | enVVeno Medical Corp HJLI · Entity 8104 | SaleCommon Stock | 75,000 | $0.27 | $20,250.00 |
DisclosureSEC source: 0001493152-20-018750 · ownership.xml · nonDerivative · entry 26 Biodyne Holding, S.A. · CIK 0001730174 · Former 10% Owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,480,433 F1 · price: 1,950,000 is the total number of shares sold and these shares were sold in multiple transactions at an average price of $0.38. The reporting person undertakes to provide to Hancock Laboratories Jaffe, Inc., any security holder of Hancock Jaffe Laboratories, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate transaction at the price set forth in footnote (1) to this Form 4. Read SEC document |
| August 19, 2020 Filed Oct 2, 2020 01:25 UTC | enVVeno Medical Corp HJLI · Entity 8104 | SaleCommon Stock | 50,000 | $0.30 | $15,000.00 |
DisclosureSEC source: 0001493152-20-018750 · ownership.xml · nonDerivative · entry 25 Biodyne Holding, S.A. · CIK 0001730174 · Former 10% Owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,555,433 F1 · price: 1,950,000 is the total number of shares sold and these shares were sold in multiple transactions at an average price of $0.38. The reporting person undertakes to provide to Hancock Laboratories Jaffe, Inc., any security holder of Hancock Jaffe Laboratories, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate transaction at the price set forth in footnote (1) to this Form 4. Read SEC document |
| August 18, 2020 Filed Oct 2, 2020 01:25 UTC | enVVeno Medical Corp HJLI · Entity 8104 | SaleCommon Stock | 50,000 | $0.34 | $17,000.00 |
DisclosureSEC source: 0001493152-20-018750 · ownership.xml · nonDerivative · entry 24 Biodyne Holding, S.A. · CIK 0001730174 · Former 10% Owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,605,433 F1 · price: 1,950,000 is the total number of shares sold and these shares were sold in multiple transactions at an average price of $0.38. The reporting person undertakes to provide to Hancock Laboratories Jaffe, Inc., any security holder of Hancock Jaffe Laboratories, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate transaction at the price set forth in footnote (1) to this Form 4. Read SEC document |
| August 14, 2020 Filed Oct 2, 2020 01:25 UTC | enVVeno Medical Corp HJLI · Entity 8104 | SaleCommon Stock | 50,000 | $0.31 | $15,500.00 |
DisclosureSEC source: 0001493152-20-018750 · ownership.xml · nonDerivative · entry 23 Biodyne Holding, S.A. · CIK 0001730174 · Former 10% Owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,655,433 F1 · price: 1,950,000 is the total number of shares sold and these shares were sold in multiple transactions at an average price of $0.38. The reporting person undertakes to provide to Hancock Laboratories Jaffe, Inc., any security holder of Hancock Jaffe Laboratories, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate transaction at the price set forth in footnote (1) to this Form 4. Read SEC document |
| August 03, 2020 Filed Oct 2, 2020 01:25 UTC | enVVeno Medical Corp HJLI · Entity 8104 | SaleCommon Stock | 70,000 | $0.32 | $22,400.00 |
DisclosureSEC source: 0001493152-20-018750 · ownership.xml · nonDerivative · entry 22 Biodyne Holding, S.A. · CIK 0001730174 · Former 10% Owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,705,433 F1 · price: 1,950,000 is the total number of shares sold and these shares were sold in multiple transactions at an average price of $0.38. The reporting person undertakes to provide to Hancock Laboratories Jaffe, Inc., any security holder of Hancock Jaffe Laboratories, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate transaction at the price set forth in footnote (1) to this Form 4. Read SEC document |
| July 31, 2020 Filed Oct 2, 2020 01:25 UTC | enVVeno Medical Corp HJLI · Entity 8104 | SaleCommon Stock | 5,000 | $0.34 | $1,700.00 |
DisclosureSEC source: 0001493152-20-018750 · ownership.xml · nonDerivative · entry 21 Biodyne Holding, S.A. · CIK 0001730174 · Former 10% Owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,775,433 F1 · price: 1,950,000 is the total number of shares sold and these shares were sold in multiple transactions at an average price of $0.38. The reporting person undertakes to provide to Hancock Laboratories Jaffe, Inc., any security holder of Hancock Jaffe Laboratories, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate transaction at the price set forth in footnote (1) to this Form 4. Read SEC document |
| July 30, 2020 Filed Oct 2, 2020 01:25 UTC | enVVeno Medical Corp HJLI · Entity 8104 | SaleCommon Stock | 25,000 | $0.32 | $8,000.00 |
DisclosureSEC source: 0001493152-20-018750 · ownership.xml · nonDerivative · entry 20 Biodyne Holding, S.A. · CIK 0001730174 · Former 10% Owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,780,433 F1 · price: 1,950,000 is the total number of shares sold and these shares were sold in multiple transactions at an average price of $0.38. The reporting person undertakes to provide to Hancock Laboratories Jaffe, Inc., any security holder of Hancock Jaffe Laboratories, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate transaction at the price set forth in footnote (1) to this Form 4. Read SEC document |
| July 21, 2020 Filed Oct 2, 2020 01:25 UTC | enVVeno Medical Corp HJLI · Entity 8104 | SaleCommon Stock | 50,000 | $0.45 | $22,500.00 |
DisclosureSEC source: 0001493152-20-018750 · ownership.xml · nonDerivative · entry 19 Biodyne Holding, S.A. · CIK 0001730174 · Former 10% Owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,805,433 F1 · price: 1,950,000 is the total number of shares sold and these shares were sold in multiple transactions at an average price of $0.38. The reporting person undertakes to provide to Hancock Laboratories Jaffe, Inc., any security holder of Hancock Jaffe Laboratories, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate transaction at the price set forth in footnote (1) to this Form 4. Read SEC document |
| July 20, 2020 Filed Oct 2, 2020 01:25 UTC | enVVeno Medical Corp HJLI · Entity 8104 | SaleCommon Stock | 150,000 | $0.43 | $64,500.00 |
DisclosureSEC source: 0001493152-20-018750 · ownership.xml · nonDerivative · entry 18 Biodyne Holding, S.A. · CIK 0001730174 · Former 10% Owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,855,433 F1 · price: 1,950,000 is the total number of shares sold and these shares were sold in multiple transactions at an average price of $0.38. The reporting person undertakes to provide to Hancock Laboratories Jaffe, Inc., any security holder of Hancock Jaffe Laboratories, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate transaction at the price set forth in footnote (1) to this Form 4. Read SEC document |
| July 17, 2020 Filed Oct 2, 2020 01:25 UTC | enVVeno Medical Corp HJLI · Entity 8104 | SaleCommon Stock | 50,000 | $0.38 | $19,000.00 |
DisclosureSEC source: 0001493152-20-018750 · ownership.xml · nonDerivative · entry 17 Biodyne Holding, S.A. · CIK 0001730174 · Former 10% Owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,005,433 F1 · price: 1,950,000 is the total number of shares sold and these shares were sold in multiple transactions at an average price of $0.38. The reporting person undertakes to provide to Hancock Laboratories Jaffe, Inc., any security holder of Hancock Jaffe Laboratories, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate transaction at the price set forth in footnote (1) to this Form 4. Read SEC document |
| July 16, 2020 Filed Oct 2, 2020 01:25 UTC | enVVeno Medical Corp HJLI · Entity 8104 | SaleCommon Stock | 50,000 | $0.38 | $19,000.00 |
DisclosureSEC source: 0001493152-20-018750 · ownership.xml · nonDerivative · entry 16 Biodyne Holding, S.A. · CIK 0001730174 · Former 10% Owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,055,433 F1 · price: 1,950,000 is the total number of shares sold and these shares were sold in multiple transactions at an average price of $0.38. The reporting person undertakes to provide to Hancock Laboratories Jaffe, Inc., any security holder of Hancock Jaffe Laboratories, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate transaction at the price set forth in footnote (1) to this Form 4. Read SEC document |
| July 06, 2020 Filed Oct 2, 2020 01:25 UTC | enVVeno Medical Corp HJLI · Entity 8104 | SaleCommon Stock | 6,450 | $0.39 | $2,515.50 |
DisclosureSEC source: 0001493152-20-018750 · ownership.xml · nonDerivative · entry 15 Biodyne Holding, S.A. · CIK 0001730174 · Former 10% Owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,105,433 F1 · price: 1,950,000 is the total number of shares sold and these shares were sold in multiple transactions at an average price of $0.38. The reporting person undertakes to provide to Hancock Laboratories Jaffe, Inc., any security holder of Hancock Jaffe Laboratories, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate transaction at the price set forth in footnote (1) to this Form 4. Read SEC document |
| July 02, 2020 Filed Oct 2, 2020 01:25 UTC | enVVeno Medical Corp HJLI · Entity 8104 | SaleCommon Stock | 57,000 | $0.40 | $22,800.00 |
DisclosureSEC source: 0001493152-20-018750 · ownership.xml · nonDerivative · entry 14 Biodyne Holding, S.A. · CIK 0001730174 · Former 10% Owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,111,883 F1 · price: 1,950,000 is the total number of shares sold and these shares were sold in multiple transactions at an average price of $0.38. The reporting person undertakes to provide to Hancock Laboratories Jaffe, Inc., any security holder of Hancock Jaffe Laboratories, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate transaction at the price set forth in footnote (1) to this Form 4. Read SEC document |
| July 01, 2020 Filed Oct 2, 2020 01:25 UTC | enVVeno Medical Corp HJLI · Entity 8104 | SaleCommon Stock | 45,000 | $0.38 | $17,100.00 |
DisclosureSEC source: 0001493152-20-018750 · ownership.xml · nonDerivative · entry 13 Biodyne Holding, S.A. · CIK 0001730174 · Former 10% Owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,168,883 F1 · price: 1,950,000 is the total number of shares sold and these shares were sold in multiple transactions at an average price of $0.38. The reporting person undertakes to provide to Hancock Laboratories Jaffe, Inc., any security holder of Hancock Jaffe Laboratories, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate transaction at the price set forth in footnote (1) to this Form 4. Read SEC document |
| June 29, 2020 Filed Oct 2, 2020 01:25 UTC | enVVeno Medical Corp HJLI · Entity 8104 | SaleCommon Stock | 68,094 | $0.39 | $26,556.66 |
DisclosureSEC source: 0001493152-20-018750 · ownership.xml · nonDerivative · entry 12 Biodyne Holding, S.A. · CIK 0001730174 · Former 10% Owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,213,883 F1 · price: 1,950,000 is the total number of shares sold and these shares were sold in multiple transactions at an average price of $0.38. The reporting person undertakes to provide to Hancock Laboratories Jaffe, Inc., any security holder of Hancock Jaffe Laboratories, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate transaction at the price set forth in footnote (1) to this Form 4. Read SEC document |
| June 26, 2020 Filed Oct 2, 2020 01:25 UTC | enVVeno Medical Corp HJLI · Entity 8104 | SaleCommon Stock | 80,000 | $0.38 | $30,400.00 |
DisclosureSEC source: 0001493152-20-018750 · ownership.xml · nonDerivative · entry 11 Biodyne Holding, S.A. · CIK 0001730174 · Former 10% Owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,281,977 F1 · price: 1,950,000 is the total number of shares sold and these shares were sold in multiple transactions at an average price of $0.38. The reporting person undertakes to provide to Hancock Laboratories Jaffe, Inc., any security holder of Hancock Jaffe Laboratories, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate transaction at the price set forth in footnote (1) to this Form 4. Read SEC document |
| June 25, 2020 Filed Oct 2, 2020 01:25 UTC | enVVeno Medical Corp HJLI · Entity 8104 | SaleCommon Stock | 100,000 | $0.40 | $40,000.00 |
DisclosureSEC source: 0001493152-20-018750 · ownership.xml · nonDerivative · entry 10 Biodyne Holding, S.A. · CIK 0001730174 · Former 10% Owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,361,977 F1 · price: 1,950,000 is the total number of shares sold and these shares were sold in multiple transactions at an average price of $0.38. The reporting person undertakes to provide to Hancock Laboratories Jaffe, Inc., any security holder of Hancock Jaffe Laboratories, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate transaction at the price set forth in footnote (1) to this Form 4. Read SEC document |
| June 24, 2020 Filed Oct 2, 2020 01:25 UTC | enVVeno Medical Corp HJLI · Entity 8104 | SaleCommon Stock | 55,530 | $0.42 | $23,322.60 |
DisclosureSEC source: 0001493152-20-018750 · ownership.xml · nonDerivative · entry 9 Biodyne Holding, S.A. · CIK 0001730174 · Former 10% Owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,461,977 F1 · price: 1,950,000 is the total number of shares sold and these shares were sold in multiple transactions at an average price of $0.38. The reporting person undertakes to provide to Hancock Laboratories Jaffe, Inc., any security holder of Hancock Jaffe Laboratories, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate transaction at the price set forth in footnote (1) to this Form 4. Read SEC document |
| June 23, 2020 Filed Oct 2, 2020 01:25 UTC | enVVeno Medical Corp HJLI · Entity 8104 | SaleCommon Stock | 80,000 | $0.43 | $34,400.00 |
DisclosureSEC source: 0001493152-20-018750 · ownership.xml · nonDerivative · entry 8 Biodyne Holding, S.A. · CIK 0001730174 · Former 10% Owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,517,507 F1 · price: 1,950,000 is the total number of shares sold and these shares were sold in multiple transactions at an average price of $0.38. The reporting person undertakes to provide to Hancock Laboratories Jaffe, Inc., any security holder of Hancock Jaffe Laboratories, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate transaction at the price set forth in footnote (1) to this Form 4. Read SEC document |
| June 22, 2020 Filed Oct 2, 2020 01:25 UTC | enVVeno Medical Corp HJLI · Entity 8104 | SaleCommon Stock | 63,186 | $0.46 | $29,065.56 |
DisclosureSEC source: 0001493152-20-018750 · ownership.xml · nonDerivative · entry 7 Biodyne Holding, S.A. · CIK 0001730174 · Former 10% Owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,597,507 F1 · price: 1,950,000 is the total number of shares sold and these shares were sold in multiple transactions at an average price of $0.38. The reporting person undertakes to provide to Hancock Laboratories Jaffe, Inc., any security holder of Hancock Jaffe Laboratories, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate transaction at the price set forth in footnote (1) to this Form 4. Read SEC document |
| June 19, 2020 Filed Oct 2, 2020 01:25 UTC | enVVeno Medical Corp HJLI · Entity 8104 | SaleCommon Stock | 80,000 | $0.46 | $36,800.00 |
DisclosureSEC source: 0001493152-20-018750 · ownership.xml · nonDerivative · entry 6 Biodyne Holding, S.A. · CIK 0001730174 · Former 10% Owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,660,693 F1 · price: 1,950,000 is the total number of shares sold and these shares were sold in multiple transactions at an average price of $0.38. The reporting person undertakes to provide to Hancock Laboratories Jaffe, Inc., any security holder of Hancock Jaffe Laboratories, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate transaction at the price set forth in footnote (1) to this Form 4. Read SEC document |
| June 18, 2020 Filed Oct 2, 2020 01:25 UTC | enVVeno Medical Corp HJLI · Entity 8104 | SaleCommon Stock | 61,640 | $0.45 | $27,738.00 |
DisclosureSEC source: 0001493152-20-018750 · ownership.xml · nonDerivative · entry 5 Biodyne Holding, S.A. · CIK 0001730174 · Former 10% Owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,740,693 F1 · price: 1,950,000 is the total number of shares sold and these shares were sold in multiple transactions at an average price of $0.38. The reporting person undertakes to provide to Hancock Laboratories Jaffe, Inc., any security holder of Hancock Jaffe Laboratories, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate transaction at the price set forth in footnote (1) to this Form 4. Read SEC document |
| June 17, 2020 Filed Oct 2, 2020 01:25 UTC | enVVeno Medical Corp HJLI · Entity 8104 | SaleCommon Stock | 203,100 | $0.48 | $97,488.00 |
DisclosureSEC source: 0001493152-20-018750 · ownership.xml · nonDerivative · entry 4 Biodyne Holding, S.A. · CIK 0001730174 · Former 10% Owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,802,333 F1 · price: 1,950,000 is the total number of shares sold and these shares were sold in multiple transactions at an average price of $0.38. The reporting person undertakes to provide to Hancock Laboratories Jaffe, Inc., any security holder of Hancock Jaffe Laboratories, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate transaction at the price set forth in footnote (1) to this Form 4. Read SEC document |
| June 16, 2020 Filed Oct 2, 2020 01:25 UTC | enVVeno Medical Corp HJLI · Entity 8104 | SaleCommon Stock | 150,000 | $0.43 | $64,500.00 |
DisclosureSEC source: 0001493152-20-018750 · ownership.xml · nonDerivative · entry 3 Biodyne Holding, S.A. · CIK 0001730174 · Former 10% Owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,005,433 F1 · price: 1,950,000 is the total number of shares sold and these shares were sold in multiple transactions at an average price of $0.38. The reporting person undertakes to provide to Hancock Laboratories Jaffe, Inc., any security holder of Hancock Jaffe Laboratories, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate transaction at the price set forth in footnote (1) to this Form 4. Read SEC document |
| June 15, 2020 Filed Oct 2, 2020 01:25 UTC | enVVeno Medical Corp HJLI · Entity 8104 | SaleCommon Stock | 100,000 | $0.42 | $42,000.00 |
DisclosureSEC source: 0001493152-20-018750 · ownership.xml · nonDerivative · entry 2 Biodyne Holding, S.A. · CIK 0001730174 · Former 10% Owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,155,433 F1 · price: 1,950,000 is the total number of shares sold and these shares were sold in multiple transactions at an average price of $0.38. The reporting person undertakes to provide to Hancock Laboratories Jaffe, Inc., any security holder of Hancock Jaffe Laboratories, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate transaction at the price set forth in footnote (1) to this Form 4. Read SEC document |
| June 11, 2020 Filed Oct 2, 2020 01:25 UTC | enVVeno Medical Corp HJLI · Entity 8104 | SaleCommon Stock | 100,000 | $0.39 | $39,000.00 |
DisclosureSEC source: 0001493152-20-018750 · ownership.xml · nonDerivative · entry 1 Biodyne Holding, S.A. · CIK 0001730174 · Former 10% Owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,255,433 F1 · price: 1,950,000 is the total number of shares sold and these shares were sold in multiple transactions at an average price of $0.38. The reporting person undertakes to provide to Hancock Laboratories Jaffe, Inc., any security holder of Hancock Jaffe Laboratories, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate transaction at the price set forth in footnote (1) to this Form 4. Read SEC document |
| June 03, 2020 Filed Jun 8, 2020 17:43 UTC | enVVeno Medical Corp HJLI · Entity 8104 | SaleCommon Stock | 1,683 | $0.31 | $521.73 |
DisclosureSEC source: 0001493152-20-010731 · ownership.xml · nonDerivative · entry 3 Biodyne Holding, S.A. · CIK 0001730174 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,355,433 Read SEC document |
| June 03, 2020 Filed Jun 8, 2020 17:43 UTC | enVVeno Medical Corp HJLI · Entity 8104 | SaleCommon Stock | 3,900 | $0.31 | $1,209.00 |
DisclosureSEC source: 0001493152-20-010731 · ownership.xml · nonDerivative · entry 2 Biodyne Holding, S.A. · CIK 0001730174 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,357,116 Read SEC document |
| June 02, 2020 Filed Jun 8, 2020 17:43 UTC | enVVeno Medical Corp HJLI · Entity 8104 | SaleCommon Stock | 220,000 | $0.33 | $72,600.00 |
DisclosureSEC source: 0001493152-20-010731 · ownership.xml · nonDerivative · entry 1 Biodyne Holding, S.A. · CIK 0001730174 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,361,016 Read SEC document |
| June 07, 2019 Filed May 14, 2020 13:46 UTC | enVVeno Medical Corp HJLI · Entity 8104 | SaleCommon Stock | 400,668 | $0.87 | $348,581.16 |
DisclosureSEC source: 0001493152-20-008636 · ownership.xml · nonDerivative · entry 1 Biodyne Holding, S.A. · CIK 0001730174 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,865,161 F1 · security: 400,668 is the total number of shares sold and these shares were sold in multiple transactions at an average price of $0.87. The reporting person undertakes to provide to Hancock Laboratories Jaffe, Inc., any security holder of Hancock Jaffe Laboratories, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate transaction at the price set forth in footnote (1) to this Form 5. Read SEC document |
| June 07, 2019 Filed May 14, 2020 13:45 UTC | enVVeno Medical Corp HJLI · Entity 8104 | SaleCommon Stock | 684,813 | $0.67 | $458,824.71 |
DisclosureSEC source: 0001493152-20-008635 · ownership.xml · nonDerivative · entry 1 Biodyne Holding, S.A. · CIK 0001730174 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,581,016 F1 · shares: 684,813 is the total number of shares sold and these shares were sold in multiple transactions at an average price of $0.67. The reporting person undertakes to provide to Hancock Laboratories Jaffe, Inc., any security holder of Hancock Jaffe Laboratories, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate transaction at the price set forth in footnote (1) to this Form 4. F1 · price: 684,813 is the total number of shares sold and these shares were sold in multiple transactions at an average price of $0.67. The reporting person undertakes to provide to Hancock Laboratories Jaffe, Inc., any security holder of Hancock Jaffe Laboratories, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate transaction at the price set forth in footnote (1) to this Form 4. Read SEC document |
| May 21, 2019 Filed May 24, 2019 21:30 UTC | enVVeno Medical Corp HJLI · Entity 8104 | OtherCommon Stock | 177,740 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001493152-19-008257 · ownership.xml · nonDerivative · entry 1 Biodyne Holding, S.A. · CIK 0001730174 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,265,829 F1 · kind: Biodyne Holding, S.A., an entity organized under the laws of Switzerland, transferred an aggregate of 177,740 shares to two of its minority shareholders in exchange for the forfeiture of thier equity ownership in Biodyne Holding, S.A. F1 · price: Biodyne Holding, S.A., an entity organized under the laws of Switzerland, transferred an aggregate of 177,740 shares to two of its minority shareholders in exchange for the forfeiture of thier equity ownership in Biodyne Holding, S.A. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.